Sona Nanotech Inc (CSE: SONA), (OTCQB: SNANF) (the “Business” or “Sona”) is happy to reveal an ingenious research study effort to be carried out with The Giacomantonio Immuno-Oncology Research Study Group (the “Research Study Group”). This research study intends to examine the effectiveness of Sona’s Targeted Hyperthermia Treatment (” THT”) innovation in not just attenuating the advancement of colorectal, breast, and cancer malignancy growth designs in mice however likewise in assisting in systemic immune reactions.
The research study presumes that the combined usage of Sona’s gold nanorods by means of its Targeted Hyperthermia Treatment, together with accurate immune modulation, will lead to raised immune activation and anti-tumor reactions within the mouse designs of colorectal cancer, breast cancer, and cancer malignancy.
Sona CEO, David Regan, commented, “ This ingenious research study will go substantially beyond our present prepare for Targeted Hyperthermia Treatment applications to check out the possibly synergistic result of its usage with specific immunotherapy treatments for cancer. In it, we intend to harness the significant capacity of immunotherapy, leveraging Sona’s biocompatible gold nanorods as a critical, catalytic component. This effort marks the start of Sona providing on the ‘mountain of information’ we devoted to establishing in assistance of our scheduled regulative submissions for human medical trial approvals.”
Dr. Carman Giacomantonio, primary private investigator of the Research study Group, commented, “ We are devoted to checking out 2 unique yet interrelated biological procedures with the possible to open the evasive Holy Grail of intra-tumoral cancer immunotherapies, called the Abscopal Impact. The very first opportunity take advantage of the kinetic excitation of gold nanorods, efficient in causing localized growth damage. This procedure exposes powerful growth neo-antigens, which can then be tactically set in motion to immune-responsive websites. This method holds the capacity of exceptionally improving and enhancing the effectiveness of the immune reaction versus cancer. Simultaneously, the 2nd measurement of our research study explores the extensive effect of intralesional immunomodulation in the context of both regional and systemic Targeted Hyperthermia Treatment. Together, these goals, if effective, might develop a tactical structure to light up the course towards groundbreaking, ingenious, and powerful immunotherapeutic interventions for colorectal cancer, breast cancer, and cancer malignancy.“
Sona CSO, Len Pagliaro, PhD, commented, “We are fired up and happy to have the chance to work together with The Giacomantonio Immuno-Oncology Research Study Group. The scheduled research studies will bring the substantial understanding and experience of Dr. Giacomantonio to bear in a sophisticated and advanced research study that will increase our understanding of both the systems and abilities of THT. The findings of this research study will assist notify and enhance our prepared first-in-human research studies as we approach that essential turning point.”
To help with the research study, the Business and the Research study Group have actually participated in a Research study Arrangement under which experiments will be performed. The experiments will check out immune reprogramming by growth antigen transfer in addition to growth reaction and immune modulation in subcutaneous growth designs following treatment with numerous immunotherapeutic interventions. The Business will cover to an optimum of $80,000, which is roughly 40% of the research study’s expected expense, which will consist of in-kind contributions of the Business and its lab. The Research study Group will supply numerous interim outcomes to be supplied to the Business and will can release findings from the research study. The research study is to be performed at the Giacomantonio Lab at Dalhousie University in Halifax, Nova Scotia. The outcomes of the research study are expected to supply information that will form part of any future regulative submissions in assistance of the advancement of its Targeted Hyperthermia Treatment.
Contact:
David Regan, CEO
+1 -902 -536 -1932
[email protected]
About Sona Nanotech Inc.
Sona Nanotech, a nanotechnology life sciences business, is establishing Targeted Hyperthermia â¢, a photothermal cancer treatment, which utilizes restorative heat to deal with strong cancer growths. The heat is provided to growths by infrared light that is taken in by Sona’s gold nanorods in the growth and re-emitted as heat. Restorative heat (44 ° C) promotes the body immune system, diminishes growths, suspends cancer stem cells, and increases growth perfusion – hence making it possible for drugs to reach all growth compartments better. The size, shape, and surface area chemistry of the nanorods target the dripping vasculature of strong growths, and the selective thermal level of sensitivity of growth tissue makes it possible for the treatment to provide tidy margins. Targeted Hyperthermia guarantees to be safe, efficient, minimally intrusive, competitive in expense, and an important accessory to drug treatment and other cancer treatments. Sona’s preliminary medical target is colorectal cancer.
Sona has actually established numerous exclusive techniques for the manufacture of gold nanoparticles which it utilizes for the advancement of both cancer treatments and diagnostic screening platforms. Sona Nanotech’s gold nanorod particles are cetyltrimethylammonium (” CTAB”) complimentary, removing the toxicity threats related to making use of other gold nanorod innovations in medical applications. It is anticipated that Sona’s gold nanotechnologies might be adjusted for usage in applications, as a safe and efficient shipment system for numerous medical treatments, based on the approval of numerous regulative boards, consisting of Health Canada and the FDA.
CAUTIONARY DECLARATION REGARDING FORWARD-LOOKING DETAILS: This news release consists of specific “positive declarations” under relevant Canadian securities legislation, consisting of declarations concerning the expected applications of Targeted Hyperthermia Treatment, Sona’s strategies to build up information in assistance of possible submissions looking for FDA and Health Canada approvals and clearances for Sona’s items under advancement and the possible effect of the scheduled research study. Positive declarations are always based upon a variety of presumptions or quotes that, while thought about affordable, go through recognized and unidentified threats, unpredictabilities, and other elements which might trigger the real outcomes and future occasions to vary materially from those revealed or suggested by such positive declarations, consisting of the threat that Sona might not have the ability to effectively acquire enough medical and other information to send regulative submissions, raise enough extra capital or establish the pictured treatment, and the threat that THT might not show to have the advantages presently expected. There can be no guarantee that such declarations will show to be precise, as real outcomes and future occasions might vary materially from those expected in such declarations. Appropriately, readers must not position unnecessary dependence on positive declarations. Sona disclaims any intent or commitment to upgrade or modify any positive declarations, whether as an outcome of brand-new info, future occasions or otherwise, other than as needed by law.
Not for circulation to United States newswire services or for dissemination in the United States.